1. Home
  2. LXEO vs CUVL Comparison

LXEO vs CUVL Comparison

Compare LXEO & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

SELL

Current Price

$3.19

Market Cap

348.7M

Sector

N/A

ML Signal

SELL

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

SELL

Current Price

$5.08

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

SELL

Company Overview

Basic Information
Metric
LXEO
CUVL
Founded
2017
1999
Country
United States
Australia
Employees
N/A
N/A
Industry
Miscellaneous
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
348.7M
374.2M
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
LXEO
CUVL
Price
$3.19
$5.08
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $20.67
N/A
AVG Volume (30 Days)
★ 1.1M
5.2K
Earning Date
11-16-2026
08-27-2026
Dividend Yield
N/A
★ 0.56%
EPS Growth
★ 39.81
N/A
EPS
N/A
★ N/A
Revenue
★ $654,000.00
N/A
Revenue This Year
N/A
$0.47
Revenue Next Year
N/A
$6.25
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$4.81
52 Week High
$10.99
$8.20

Technical Indicators

Market Signals
Indicator
LXEO
CUVL
Relative Strength Index (RSI) 50.17 43.75
Support Level $2.72 $4.86
Resistance Level $3.56 $6.00
Average True Range (ATR) 0.38 0.26
MACD 0.04 0.04
Stochastic Oscillator 25.62 21.54

Price Performance

Historical Comparison
LXEO
CUVL

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: